久久精品欧美日韩精品,中文字幕av区四区三区二区一区,久久久久久精品免费免费麻辣,欧美日韩免费高清大片

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73198KIF5B（E15）-RET（E12） V804L/BaF3

KIF5B（E15）-RET（E12） V804L/BaF3
名稱 KIF5B（E15）-RET（E12） V804L/BaF3
型號 CBP73198
報價
特點 KIF5B（E15）-RET（E12） [V804L]/BaF3,母細胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細內(nèi)容
CBP73198
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12) [V804L]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804L]/BaF3

CBP73198 WB.png


2. Sanger of KIF5B-RET [V804L]/BaF3

CBP73198 sanger1.png


CBP73198 sanger2.png


3. Anti-proliferation assay

CBP73198 fig.jpg

Figure 4.CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804L Cells (C1).




如果你對CBP73198KIF5B（E15）-RET（E12） V804L/BaF3感興趣，想了解更詳細的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細地址：

  • 補充說明：

  • 驗證碼：

    請輸入計算結(jié)果（填寫阿拉伯數(shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
国产69精品一区二区三区| 蜜臀av国产精品久久久久| 人与嘼一区二区三区| 亚洲成av一区二区三区| 韩国午夜理伦三级理论电影| 亚洲欧洲欧美中文日韩| 精品天堂色吊丝一区二区| 亚洲国产精品国揄产拍| 欧美精品在线观看不卡| 欧美日韩制服丝袜中文字幕| 日韩一区二区三区视频| 日本视频高清一区二区| 欧洲日韩在线观看一区二区三区视频| 国产一二三区亚洲欧美| 激情综合婷婷丁香五月俺来也| 一区二区三区四区欧美日韩亚洲| 欧美日韩一区二区三区大片在线观看| 国产v亚洲v天堂无码| 一级国产一级日韩一级欧美| 精品日韩欧美一区在线播放| 中文字幕久久中文字幕综合网| 国产一级精品无码免费视频| 国产欧美在线观看精品一区污| 久久久区一区二区三| 国产精品亚洲一区二区三区欲| 夫妻久久久久久久久了| 国产黄色三级三级三级看三级| 国产精品国语对白在线观看| 日韩精品欧美亚洲国产最大| 日韩国产av一区二区| 久久蜜臀亚洲一区二区| 久久免费少妇高潮视频| av网址在线播放大全| 久久久久人妻精品明星换脸| 国产精品久久久久99999| 亚洲精品一区二区三区中文字幕| 欧美日韩精品一区二区三区激情在线| 久久秘一区二区三区| 国产日欧一片内射午夜| 日韩欧美精品在线中文字幕| 色狠狠av一区二区三区香蕉|